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Abstract
Objective: We describe the first reported case of a phosphaturic mesenchymal tumour, mixed connective tissue variant,
invading the temporal bone.
Case report: A female patient presented with increasing deafness. On examination there appeared to be a mass behind
an intact tympanic membrane. Further radiological investigation showed a vascular mass occupying the middle ear,
mastoid and internal auditory meatus. This was surgically resected and revealed to be a benign phosphaturic
mesenchymal tumour, mixed connective tissue variant. The tumour recurred a year later, presenting as facial nerve
palsy. A revision procedure was carried out; the tumour was excised with the sacrifice of a segment of the facial nerve,
and a facial-hypoglossal nerve anastomosis was performed.
Conclusion: This case report highlights the occurrence of this benign but sometimes aggressive tumour, of which both
clinicians and pathologists should be aware. Early recognition of the condition remains of utmost importance to minimise
the debilitating consequences of long-term osteomalacia in affected patients, and to prevent extracranial and intracranial
complications caused by the tumour.
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Introduction
The phosphaturic mesenchymal tumour, mixed connective
tissue variant, represents an extremely rare, distinctive
tumour that is frequently associated with oncogenic osteoma-
lacia. Expression of fibroblast growth factor-23, a recently
described protein putatively implicated in renal tubular phos-
phate loss, has been shown in a number of mesenchymal
tumours with oncogenic osteomalacia. Oncogenic osteoma-
lacia is a paraneoplastic syndrome wherein the presence of
a tumour, often of mesenchymal origin, results in phosphate
wasting and hypophosphataemia. It is thought that the
tumour cells produce a peptide hormone like substance,
identified as fibroblast growth factor-23, which is a physio-
logical regulator of phosphate balance.
There are over a hundred cases of phosphaturic mesench-
ymal tumour, mixed connective tissue variant, described in
literature. The tumours mainly involve the axial skeleton,
the soft tissues and the paranasal sinuses. The vast majority
of these tumours are benign, and recurrence and metastasis
are rare even in the malignant cases. A significant
number of these reported cases had initially been wrongly
diagnosed; the misdiagnosis was detected by subsequent
expert reviews.
The phosphaturic mesenchymal tumour, mixed connec-
tive tissue variant, remains a largely unknown entity,
which continues to be misdiagnosed by most clinicians and
pathologists.
We describe the first reported case of the tumour invading
the temporal bone with intracranial extension. This led to
deafness and facial paralysis, even after resection of the
tumour with a subtotal petrosectomy. The diagnostic and
management dilemmas are discussed.
Case report
A 71-year-old female patient presented with hearing loss in
the right ear, which for 12 months had been gradually wor-
sening. She had a history of congenital deafness in the left
ear of unknown cause. She was also a type II diabetic and
suffered from depression.
On examination of the patient’s left ear, a reddish mass
was visualised behind an intact tympanic membrane
(Figure 1). The rest of the ear, nose and throat examination,
including cranial nerve examination, was unremarkable. An
audiogram showed moderate sensorineural hearing loss in
the left ear. A magnetic resonance imaging (MRI) scan
showed an enhancing vascular mass, which occupied the
right middle ear and mastoid, extended to the lateral third
of the internal auditory meatus, and encased the tympanic
segment of the right internal carotid artery (Figure 2).
The patient subsequently underwent a tympanotomy.
Pathomorphological examination of the tumour showed a
haemangiopericytoma-like pattern with a moderately cellular
proliferation of bland, round to oval cells, often arranged
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around thick-walled vessels. Due to the presence of typical
‘grungy’ calcification and a chondroid-like matrix in some
areas, a histological diagnosis of mesenchymal phosphaturic
tumour was made (Figure 3a). The patient had no clinical or
metabolic signs of osteomalacia.
The patient underwent a petrosectomy with complete
removal of the tumour. The tumour was extremely vascular,
occupying the middle ear and mastoid, eroding into the
lining of the sigmoid sinus, and invading the middle fossa
dura, which had to be excised and primarily repaired. The
macroscopic appearance of the tumour completely filling
the mastoid cavity can be seen in Figure 4. Although the
facial canal was intact, the tumour had to be peeled off the
area surrounding the geniculate ganglion. The patient was
advised post-operative radiotherapy, which she refused.
The patient presented a year later with a progressive,
House–Brackmann grade IV, infranuclear facial nerve
palsy on the right side. A repeated MRI scan showed recur-
rence of the tumour in the area of the genu and the cerebel-
lopontine angle. A revision procedure was carried out and the
tumour was macroscopically removed, with the sacrifice of a
segment of the facial nerve at the genu. A facial–hypoglossal
nerve anastomosis was carried out. The pathology examin-
ation confirmed the tumour to be a benign mesenchymal
phosphaturic tumour, with infiltration of the peripheral
nerves (Figure 3b).
Discussion
In 1987, Weidner and Santa Cruz published the first compre-
hensive study of mesenchymal tumours associated with
oncogenic osteomalacia, and coined the term ‘phosphaturic
mesenchymal tumour, mixed connective tissue variant’.1
As part of this study, they reviewed previous cases published
under a variety of diagnoses and reclassified them as a phos-
phaturic mesenchymal tumour, mixed connective tissue
variant. However, as Folpe et al.2 demonstrated in 2004,
this entity is still relatively unknown to both clinicians and
pathologists, and continues to be misdiagnosed. (Folpe
et al.2 reviewed 32 mesenchymal tumours and concluded
that more than half of these had been wrongly diagnosed.)
Phosphaturic mesenchymal tumours are rare neoplasms
often described as ‘strange tumours that occur in strange
places’. Approximately 53 per cent have been reported
occurring in bone, 45 per cent in soft tissues and 3 per
cent in skin. In less than 5 per cent of cases, the tumours
have been localised to the craniofacial region, involving
the paranasal sinuses and mandible. Our case is the first
that reports localisation of the tumour in the temporal
bone, with intracranial extension.
Most osteomalacia-associated mesenchymal tumours have
been found to express fibroblast growth factor-23, as con-
firmed in the review by Folpe et al.,2 and by other investi-
gators using immunohistochemistry, reverse transcription
polymerase chain reaction, western blot and in-situ hybridis-
ation techniques.3 Fibroblast growth factor-23 inhibits
sodium-phosphate co-transporters in the proximal tubular
cells of the kidney in vitro (via a decrease in the sodium
phosphate transporter-type 2a (NPT2a) transporters).4 It
has also been shown to inhibit 25-hydroxyvitamin D to
1,25-dihydroxyvitamin D. Furthermore, mice injected with
FIG. 1
Examination of the patient’s left ear showed a reddish mass in the
middle ear behind an intact tympanic membrane.
FIG. 2
(a) Axial and (b) sagittal magnetic resonance images show the
enhancing mass occupying the middle ear, mastoid and petrous tem-
poral bone.
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fibroblast growth factor-23 showed reduced serum phos-
phorus levels, increased phosphate excretion and features
of osteomalacia.5 Similarly, most phosphaturic mesenchy-
mal tumours have been found to over-express fibroblast
growth factor-23, and thus exhibit clinical features of
osteomalacia.
Patients affected by phosphaturic mesenchymal tumours
typically exhibit the following clinical features of osteomala-
cia: bone pain, muscle weakness and fatigue. The biochemical
markers include hypophosphataemia, hyperphosphaturia,
decreased tubular phosphate reabsorption, and inappropriately
normal or low 1,25-dihydroxyvitamin D3. Interestingly, not
all patients show clinical or laboratory signs of osteomalacia,
one possible explanation being that the tumour secretes inac-
tive or insufficient fibroblast growth factor-23.2 Patients may
present with signs of the tumour, as in the current case
report, wherein the patient initially presented with increasing
deafness and then re-presented with recurrent tumour and pro-
gressive facial nerve palsy.
A prototypical phosphaturic mesenchymal tumour, mixed
connective tissue variant, contains neoplastic cells that are
typically spindle to stellate shaped, with low grade nuclear
atypia and low mitotic activity. The cells are embedded in
a distinctive myxoid to chondromyxoid matrix that often
contain foci of ‘grungy’ or flocculent calcification. Other
features of the tumour include osteoclast-like giant cells,
mature fat, woven bone and areas of microcystic change.
Some morphological variants of the tumour have been
described. As in the case described here, a more haemangio-
pericytoma-like pattern may occur, particularly in tumours of
the sinonasal tract. Nevertheless, the immunohistochemical
stains for pan-cytokeratin, desmin, S-100 and cluster of
differentiation 34 glycoprotein are predominantly negative
in the neoplastic cells of all morphological variants.2,6
• The phosphaturic mesenchymal tumour, mixed
connective tissue variant, is extremely rare
• It is frequently associated with oncogenic
osteomalacia
• Most of these tumours are benign; recurrence and
metastasis are rare, but can be locally aggressive
• Early diagnosis minimises long-term osteomalacia
sequelae and prevents extracranial and
intracranial complications
Complete resection of the tumour is the current treatment of
choice for phosphaturic mesenchymal tumour, mixed con-
nective tissue variant. The biochemical and clinical signs
of osteomalacia tend to normalise within weeks following
successful resection of the tumour, and it has been estimated
that 90 per cent of patients are cured with complete resec-
tion.7 Even in histologically malignant tumours, local recur-
rence or distant metastasis is extremely rare.2 Of the reported
cases in which radiotherapy was used post-resection to treat
malignant phosphaturic mesenchymal tumours, mixed con-
nective tissue variant, only two showed limited success. It
is hypothesised that the capacity of the tumour to produce
fibroblast growth factor-23 might be altered by radiother-
apy.8 In the case reported here, although the tumour appeared
histologically benign, it showed an aggressive behaviour;
thus we offered the patient radiotherapy post-operatively,
which she refused.
FIG. 3
Photomicrographs showing (a) the tumour (H&E; 20X) (inset
shows typical ‘grungy’ calcifications (H&E; 10X)) and (b) infiltra-
tion of cells of the recurrent tumour in peripheral nerve tissue (H&E;
2X) (inset shows the immunohistochemistry for S-100, with brown
stained peripheral nerve tissue (10X)).
FIG. 4
Macroscopic appearance of the tumour completely filling the
mastoid cavity.
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Conclusion
The phosphaturic mesenchymal tumour, mixed connective
tissue variant, is a very rare neoplasm. This is the first
reported case of the tumour involving the temporal bone.
This case report highlights the occurrence of this entity, in
an effort to raise its profile amongst clinicians and pathol-
ogists. Further similar cases need to be reported in the litera-
ture in order to understand the tumour’s associated clinical
behaviour and to determine the best modality with which
to treat this tumour.
Although most reported cases are benign and slow-
growing, they can be aggressive and recurrent, as this case
report demonstrates.
Early recognition of the condition remains of the utmost
importance to minimise the debilitating consequences of
long-term osteomalacia in affected patients, and to prevent
extracranial and intracranial complications caused by the
tumour.
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